MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
27.52
-0.31
-1.11%
Pre Market: 27.22 -0.3 -1.09% 04:40 09/15 EDT
OPEN
28.00
PREV CLOSE
27.83
HIGH
28.10
LOW
27.38
VOLUME
14.70K
TURNOVER
0
52 WEEK HIGH
30.96
52 WEEK LOW
19.69
MARKET CAP
4.74B
P/E (TTM)
12.44
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACAD last week (0907-0911)?
Weekly Report · 23h ago
Acadia Pharmaceuticals Reaches Preliminary Derivative Lawsuit Settlement
TipRanks · 3d ago
Acadia Pharmaceuticals Receives Preliminary Court Approval Of Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action
Benzinga · 3d ago
Weekly Report: what happened at ACAD last week (0831-0904)?
Weekly Report · 09/07 09:26
Should EU Approval of First Rett Syndrome Therapy DAYBU Reshape ACADIA Pharmaceuticals’ (ACAD) Investment Narrative?
Simply Wall St · 09/07 05:23
ACADIA Pharmaceuticals (ACAD) Wins EU Approval For DAYBU, Is The 16% Upside Still There?
Simply Wall St · 09/05 22:22
Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
TipRanks · 09/03 10:56
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Seeking Alpha · 08/31 18:57
More
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.